Axsome Therapeutics, Inc. Dividend History (AXSM)
Axsome Therapeutics, Inc. does not pay dividends currently 😔
They might in the future, check back soon!
About Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to developing therapies for central nervous system (CNS) disorders. Founded in 2012 and headquartered in New York City, the company focuses on novel mechanisms to address significant unmet medical needs in patients. Led by its CEO, Dr. Herriot Tabuteau, Axsome has made considerable progress in its pipeline, including treatments for depression, migraine, and narcolepsy, among others. The company's revenue stream is anchored in its innovative drug development efforts, showcasing a commitment to improving patient outcomes. Axsome's approach combines clinical and regulatory expertise to expedite the delivery of effective CNS therapies to the market.
Jazz Pharmaceuticals plc
Viking Therapeutics, a mid-cap biotech company, has seen its stock price rise by nearly 200% since January 2024. While the company's leading candidate, VK2735, has promising phase 2 results, the author suggests that the company may be overvalued compared to other mid-cap drugmakers. However, the author also highlights the potential of Viking's pipeline and recommends that investors closely examine the company.
The Motley Fool · Published on Sun Nov 17 2024
In a market broadly priced for perfection, three Motley Fool contributors have identified what they believe are bargain stocks to buy: Axsome Therapeutics, CRISPR Therapeutics, and Pfizer.
The Motley Fool · Published on Sat Oct 19 2024